PMID- 26949616
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160307
LR  - 20200929
IS  - 2222-3959 (Print)
IS  - 2227-4898 (Electronic)
IS  - 2222-3959 (Linking)
VI  - 9
IP  - 1
DP  - 2016
TI  - Predictors of short-term outcomes related to central subfield foveal thickness 
      after intravitreal bevacizumab for macular edema due to central retinal vein 
      occlusion.
PG  - 86-92
LID - 10.18240/ijo.2016.01.15 [doi]
AB  - AIM: To investigate the predictive factors for short-term effects of intravitreal 
      bevacizumab injections on central subfield foveal thickness (CSFT) in patients 
      with macular edema (ME) secondary to central retinal vein occlusion (CRVO). 
      METHODS: This was a retrospective study in 60 eyes treated with intravitreal 
      bevacizumab injections for ME due to CRVO. Follow-up was three months. The Early 
      Treatment Diabetic Retinopathy Study (ETDRS) score and CSFT measured by 
      spectral-domain optical coherence tomography (SD-OCT) were used to observe the 
      changes in best-corrected visual acuity (BCVA). Baseline BCVA, CSFT, age, CRVO 
      duration and the presence of cystoid macular edema (CME) or subretinal fluid 
      (SRF) were analyzed as potential predictive factors of the effects of 
      intravitreal bevacizumab injections. RESULTS: BCVA improved from 0.9 logMAR at 
      baseline to 0.6 logMAR at 3mo, which was associated with a significant reduction 
      in CSFT from 721 microm to 392 microm 3mo after injection. About 50% of CME cases and 
      more than 90% of SRF cases responded to treatment with a complete resolution at 
      3mo. Age (P=0.036) and low baseline CSFT (P=0.037) were associated with a good 
      3-month prognosis. Patients >60 years old achieved better CME resolution 
      (P=0.031) and lower CSFT at 3mo (305 microm vs 474 microm, P=0.003). CONCLUSION: 
      Intravitreal bevacizumab significantly improved visual acuity and CSFT in 
      patients with CRVO after 3mo. Older age and lower baseline CSFT were good 
      predictors of short-term CSFT outcomes. The retinal thickness response to 
      bevacizumab might depend on the resolution of CME rather than SRF.
FAU - Wang, Mei-Zi
AU  - Wang MZ
AD  - Department of Ophthalmology, Beijing Tiantan Hospital, Capital Medical 
      University, Beijing 100050, China.
FAU - Feng, Kang
AU  - Feng K
AD  - Peking University Eye Center, Peking University Third Hospital, Key Laboratory of 
      Vision Loss and Restoration, Ministry of Education, Beijing 100191, China.
FAU - Lu, Yao
AU  - Lu Y
AD  - Peking University Eye Center, Peking University Third Hospital, Key Laboratory of 
      Vision Loss and Restoration, Ministry of Education, Beijing 100191, China.
FAU - Qian, Fang
AU  - Qian F
AD  - Peking University Eye Center, Peking University Third Hospital, Key Laboratory of 
      Vision Loss and Restoration, Ministry of Education, Beijing 100191, China.
FAU - Lu, Xin-Rong
AU  - Lu XR
AD  - Peking University Eye Center, Peking University Third Hospital, Key Laboratory of 
      Vision Loss and Restoration, Ministry of Education, Beijing 100191, China.
FAU - Zang, Si-Wen
AU  - Zang SW
AD  - Peking University Eye Center, Peking University Third Hospital, Key Laboratory of 
      Vision Loss and Restoration, Ministry of Education, Beijing 100191, China.
FAU - Zhao, Lin
AU  - Zhao L
AD  - Peking University Eye Center, Peking University Third Hospital, Key Laboratory of 
      Vision Loss and Restoration, Ministry of Education, Beijing 100191, China.
LA  - eng
PT  - Journal Article
DEP - 20160118
PL  - China
TA  - Int J Ophthalmol
JT  - International journal of ophthalmology
JID - 101553860
PMC - PMC4768500
OTO - NOTNLM
OT  - bevacizumab
OT  - central retinal vein
OT  - central subfield foveal thickness
OT  - intravitreal injection
OT  - macular edema
EDAT- 2016/03/08 06:00
MHDA- 2016/03/08 06:01
PMCR- 2016/01/18
CRDT- 2016/03/08 06:00
PHST- 2014/12/05 00:00 [received]
PHST- 2015/02/25 00:00 [accepted]
PHST- 2016/03/08 06:00 [entrez]
PHST- 2016/03/08 06:00 [pubmed]
PHST- 2016/03/08 06:01 [medline]
PHST- 2016/01/18 00:00 [pmc-release]
AID - ijo-09-01-086 [pii]
AID - 10.18240/ijo.2016.01.15 [doi]
PST - epublish
SO  - Int J Ophthalmol. 2016 Jan 18;9(1):86-92. doi: 10.18240/ijo.2016.01.15. 
      eCollection 2016.